The management of neuroendocrine tumours is challenging when curative surgery is ruled out because of distant metastases. We report a case of gastrointestinal carcinoid with bilateral ovarian metastases in a 50-year-old female who received octreotide therapy followed by peptide receptor radionuclide therapy and surgery thereafter. Somatostatin receptor expression on neuroendocrine tumours has implications in diagnosis and therapy. 68Ga-DOTA-NOC PET is a recent advancement in the field of somatostatin receptor imaging. The lesions which demonstrate tracer uptake on positron emission tomographic studies can be further planned for treatment with octreotide and 177Lu-DOTA-TATE. The case in discussion responded well to non-invasive treatment options before proceeding to definitive surgical management. © The Author 2012. Published by Oxford University Press. All rights reserved.
CITATION STYLE
Singla, S., Gupta, S., Reddy, R. M., Durgapal, P., & Bal, C. S. (2012). 68Ga-dOTA-NOC PET and peptide receptor radionuclide therapy in management of bilateral ovarian metastases from gastrointestinal carcinoid. Japanese Journal of Clinical Oncology, 42(12), 1202–1206. https://doi.org/10.1093/jjco/hys172
Mendeley helps you to discover research relevant for your work.